- Latest available (Revised)
- Point in Time (01/04/2013)
- Original (As made)
Version Superseded: 01/04/2016
Point in time view as at 01/04/2013.
There are currently no known outstanding effects for the The Medicines (Products for Human Use) (Fees) Regulations 2013 (revoked).
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
(This note is not part of the Regulations)
These Regulations revoke and re-enact in consolidated form, with some amendments, the Medicines (Products for Human Use) (Fees) Regulations 2012 (“the 2012 Regulations”) and the Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2012. They make amendments to the Medicines for Human Use (Clinical Trials) Regulations 2004 (“the Clinical Trials Regulations”).
These Regulations make provision for the fees payable under the Medicines Act 1971 and other fees payable in respect of EU obligations relating to marketing authorisations, licences and certificates and registrations in respect of medicinal products for human use.
The fees prescribed in the Regulations are revised on an annual basis and based on an assessment of the costs associated with a range of licensing requirements and functions. The fee amounts specified in these Regulations are set in line with a consultation document issued by the Medicines and Healthcare products Regulatory Agency (“MHRA”) on 19th October 2012. A summary of the consultation responses is published on the MHRA's website (www.mhra.gov.uk).
In general these Regulations provide for an increase in all medicines fees to reflect the higher costs for the MHRA in carrying out related regulatory activities. They also include consequential amendments arising out of the making of the Human Medicines Regulations 2012, some simplification measures, provisions to implement the fees necessary to carry out regulatory activities in relation to brokers of medicinal products, the import, manufacture or wholesale active substances and pharmacovigilance service providers.
Parts 2 to 9 and 11 and 12 and Schedules 2 and 3 provide for capital fees to be payable in connection with pre-application meetings; applications for, or variations to, authorisations, manufacturer's licences, wholesale dealer's licences, clinical trial authorisations, broker's registrations, active substance registrations, traditional herbal registrations and certificates permitting the export of medicinal products; assistance in obtaining or renewing marketing authorisations in other EEA States; the assessment of labels and leaflets; renewals of certain manufacturer's licences; and inspections. Most of the fees were previously provided for by the 2012 Regulations (as amended).
However, these Regulations also—
provide new fees in relation to brokers of medicinal products and persons who import, manufacture or distribute an active substance;
provide new fees in relation to persons who provide a pharmacovigilance service;
simplify the fees payable for clinical trial authorisations;
reduce the fees payable by new manufacturers of simple substances that also serve as active pharmaceutical ingredients;
make minor technical changes to variations of marketing authorisations implementing Commission Regulation (EC) No 1234/2008 as amended by Commission Regulation (EC) No 712/2012.
Part 10 and Schedule 4 provide for periodic fees in connection with authorisations, registrations and licences.
Part 13 and Schedule 5 provides for fees in relation to homoeopathic medicinal products.
Part 14 and Schedules 6, 7 and 8 deal with the time for payment and waiver or refund of both capital and periodic fees in specified circumstances. Schedules 6 and 7 now also apply to applications for a broker's registration or an active substance registration.
Part 15 makes consequential amendments to the Clinical Trials Regulations to update cross-references to these Regulations.
Part 16 of these Regulations revokes and makes savings provisions in relation to earlier Regulations relating to fees for medicinal products for human use and medical devices for human use.
An impact assessment has not been prepared for this instrument as no impact on the private or voluntary sector is foreseen.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: